5 systems detail plans to fast-track breakthrough pancreatic cancer drug
On Aug. 26, the FDA approved daraxonrasib, brand name Rasonque, for adults with advanced pancreatic cancer that has stopped responding to chemotherapy. The approval came three months after a landmark study found the drug extended progression-free survival by a median of 8.5 months, kicking off a wave of patient interest that had health system leaders […] The post 5 systems detail plans to fast-track breakthrough pancreatic cancer drug appeared first on Becker's Hospital Review | Healt...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.